Transarterial Radioembolization: Patient Selection and Microsphere Characteristics

Abstract

AbstractTransarterial radioembolization (TARE) using yttrium-90 (90Y)-labeled microspheres has become increasingly adopted as an important treatment option for primary and metastatic hepatic malignancies. Rigorous patient evaluation and selection prior to TARE is critical to optimize the benefits of this therapy and minimize adverse events. Equally important for ensuring a successful 90Y program is a broad knowledge of the fundamental physical characteristics, manufacturing processes, and supply and delivery parameters of the different commercially available microspheres and those currently under investigation for use in the United States.